Publication Date:
2010-11-19
Description:
Abstract 1386 Background: Hyperacute TLS, defined as a rise in uric acid, potassium, lactate dehydrogenase (LDH), and/or phosphate that occurs within 4.5 hours and peaks 24–48 hours after flavopiridol, has been described in up to 40% of pts with CLL treated with this agent. Methods: A retrospective analysis of 116 pts with relapsed or refractory CLL treated with single agent flavopiridol at the Ohio State University on phase I or II protocols was conducted to determine predictive factors for TLS. Pts received flavopiridol 30–50 mg/m2 bolus + 30–50 mg/m2 4-hour continuous IV infusion (CIVI) on days 1, 8, 15, and 22 every 35 days or days 1, 8, and 15 every 28 days. Results: In 116 pts, the median age was 60 (range, 31–84), median number of prior therapies was 4 (range, 1–14), 69% pts were male, 79% were Rai stage III-IV, 53% had bulky disease ≥ 10 cm, 52% had splenomegaly, and 69% had del(17p) and/or del(11q). Median pre-treatment laboratory values included B2-microglobulin (B2M) 4.4 (range, 0.8–14.9), absolute lymphocyte count (ALC) 7134/mm3 (range, 0–266,310), white blood cell count (WBC) 13,950/mm3 (range, 1,300-314,500), and LDH 199 U/L (range, 102–654). The incidence of TLS was 46% (95% CI: 36%-55%), with 14 of 53 pts (26%) with TLS requiring dialysis. In univariable analyses using logistic regression, variables associated with the occurrence of TLS were female gender (p
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink